Comparing The Fixed Combination Brimonidine-timolol Versus Fixed Combination Dorzolamide-timolol In Patients With Elevated Intraocular Pressure

Purpose: To evaluate the efficacy of fixed combination brimonidine-timolol (FCBT) versus fixed combination dorzolamide-timolol (FCDT) given twice daily in patients with primary open angle glaucoma (POAG) or ocular hypertension (OH). Design: Prospective, multicentre, masked-observer, crossover comparison. Participants: Sixteen patients with POAG and 14 with OH. Methods: The participants of the study were washed out from their previous medication and randomized to fixed FCBT or FCDT for the first 4-week treatment period. Subjects then were washed for 4 weeks and started on the opposite medication for the second 4-week period. Intraocular pressure (IOP) was measured with a Goldmann applanation tonometer at 8:00 a.m., 12:00 noon and 4:00 p.m. at each baseline and at the end of each treatment period. Unsolicited ocular adverse events were also recorded. Main outcome measures: Comparison of the IOP lowering effect of FCBT and FCDT. Results: The baseline mean diurnal IOP for all 30 subjects (30 eyes) was 22.9 ± 1.6 mmHg. Both fixed combinations significantly reduced IOP compared with baseline (p < 0.00001). The mean diurnal IOP following 4 weeks of therapy was 15.0 ± 2.1 mmHg for FCBT and 15.4 ± 2.1 mmHg for FCDT (p = 0.510). The mean diurnal IOP reduction was 7.8 ± 1.9 mmHg for FCBT and 7.4 ± 1.8 mmHg for FCDT (p = 0.430). Overall, 14 subjects complained about ocular adverse events: two only for FCBT, seven only for FCDT and five for both drugs. Although there was no significant difference between the number of subjects that reported ocular adverse events with FCBT (n = 7) and FCDT (n = 12) (p = 0.359), FCDT caused more ocular stinging upon instillation (n = 9) than FCBT (n = 1) (p = 0.027). Conclusion: This study suggests that FCBT and FCDT, each given twice daily, have similar efficacy in patients with POAG or OH. © 2007 Librapharm Limited.234683689Alward, W.L., Medical management of glaucoma (1998) N Engl J Med, 339, pp. 1298-1307Stewart, W.C., Sharpe, E.D., Harbin Jr, T.S., Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure (2000) Am J Ophthalmol, 129, pp. 723-727Francis, B.A., Du, L.T., Berke, S., Comparing the fixed combination dorzolamide-timolol (Cosopt) to concomitant administration of 2% dorzolamide (Trusopt) and 0.5% timolol - a randomized controlled trial and a replacement study (2004) J Clin Pharm Ther, 29, pp. 375-380Hutzelmann, J., Owens, S., Shedden, A., Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: A clinical equivalence study. International Clinical Equivalence Study Group (1998) Br J Ophthalmol, 82, pp. 1249-1253Sall, K.N., Greff, L.J., Johnson-Pratt, L.R., Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: Six-month comparison of efficacy and tolerability (2003) Ophthalmology, 110, pp. 615-624Zeyen, T., Target pressures in glaucoma (1999) Bull Sot Beige Ophtalmol, 274, pp. 61-65Alm, A., Widengard, I., Kjellgren, D., Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol (1995) Br J Ophthalmol, 79, pp. 12-16Kass, M.A., Hodapp, E., Gordon, M., Part I. Patient administration of eyedrops: Interview (1982) Ann Ophthalmol, 14, pp. 775-779Kass, M.A., Hodapp, E., Gordon, M., Patient administration of eyedrops: Observation (1982) Part II. Ann Ophthalmol, 14, pp. 889-893Cvenkel, B., Inar, A., Ocular surface changes induced by topical antiglaucoma monotherapy (2002) Ophthalmologica, 216, pp. 175-179Noecker, R., Effects of common ophthalmic preservatives on ocular health (2001) Adv Ther, 18, pp. 205-215Boyle, J.E., Ghosh, K., Gieser, D.K., A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide (1998) Ophthalmology, 105, pp. 1945-1951Strahlman, E., Tipping, R., Vogel, R., International Dorzolamide Study Group. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol (1995) Arch Ophthalmol, 113, pp. 1009-1016Wilkerson, M., Cyrlin, M., Lippa, E.A., Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor (1993) Arch Ophthalmol, 111, pp. 1343-1350Rusk, C., Sharpe, E., Laurence, J., Dorzolamide Comparison Study Group. Comparison of the efficacy and safety of 2% dorzolamide and 0.5% betaxolol in the treatment of elevated intraocular pressure (1998) Clin Ther, 20, pp. 454-466O'Donoghue, E.P., UK and Ireland Latanoprost Study Group. A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: A 3 month, randomised study (2000) Br J Ophthalmol, 84, pp. 579-582Araie, M., Kitazawa, Y., Azuma, I., The efficacy and safety of dose escalation of dorzolamide used in combination with other topical antiglaucoma agents (2003) J Ocul Pharmacol Ther, 19, pp. 517-525Sharpe, E.D., Day, D.G., Beischel, C.J., Brimonidine purite 0.15% versus dorzolamide 2% each given twice daily to reduce intraocular pressure in subjects with open angle glaucoma or ocular hypertension (2004) Br J Ophthalmol, 88, pp. 953-956Kampik, A., Arias-Puente, A., O'Brart, D.P., Intraocular pressure-lowering effects of latanoprost and brimonidine therapy in patients with open-angle glaucoma or ocular hypertension: A randomized observer-masked multicenter study (2002) J Glaucoma, 11, pp. 90-96Schuman, J.S., Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension (1996) Surv Ophthalmol, 41 (SUPPL.), pp. S27-S37DuBiner, H.B., Mroz, M., Shapiro, A.M., Brimonidine vs. Latanoprost Study Group. A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: A three-month, multicenter, randomized, double-masked, parallel-group trial (2001) Clin Ther, 23, pp. 1969-1983Walters, T.R., Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: A review of safety, efficacy, dose response, and dosing studies (1996) Surv Ophthalmol, 41 (SUPPL.), pp. S19-S26Nordland, J.R., Pasaquale, L.R., Robin, A.L., The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine (1995) Arch Ophthalmol, 113, pp. 77-83Whitson, J.T., Henry, C., Hughes, B., Comparison of the safety and efficacy of dorzolamide 2% and brimonidine 0.2% in patients with glaucoma or ocular hypertension (2004) J Glaucoma, 13, pp. 168-173Wang, R.F., Serle, J.B., Gagliuso, D.J., Comparison of the ocular hypotensive effect of brimonidine, dorzolamide, latanoprost, or artificial tears added to timolol in glaucomatous monkey eyes (2000) J Glaucoma, 9, pp. 458-462Carrasco Font, C., Arias Puente, A., Garcia Saenz, M.C., Efficiency of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers [in Spanish] (2004) Arch Soc Esp Oftalmol, 79, pp. 163-168Strohmaier, K., Snyder, E., DuBiner, H., The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components (1999) Ophthalmology, 106 (SUPPL.), pp. 1-9Craven, E.R., Walters, T.R., Williams, R., Brimonidine and timolol fixed-combination therapy versus monotherapy: A 3-month randomized trial in patients with glaucoma or ocular hypertension (2005) J Ocul Pharmacol Ther, 21, pp. 337-348Goñi, F.J., The Brimonidine/Timolol Fixed Combination Study Group. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension (2005) Eur J Ophthalmol, 15, pp. 581-590Solish, A.M., DeLucca, P.T., Cassel, D.A., Dorzolamide/timolol fixed combination versus concomitant administration of brimonidine and timolol in patients with elevated intraocular pressure: A 3-month comparison of efficacy, tolerability, and patient-reported measures (2004) J Glaucoma, 13, pp. 149-15